<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00913094</url>
  </required_header>
  <id_info>
    <org_study_id>07001-M2-1-2-3</org_study_id>
    <nct_id>NCT00913094</nct_id>
  </id_info>
  <brief_title>Bioimpedance Evaluation of Therapeutic Titration in Essential, Refractory Hypertension</brief_title>
  <acronym>BETTER-HTN</acronym>
  <official_title>Bioimpedance Evaluation of Therapeutic Titration in Essential, Refractory Hypertension (BETTER-HTN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioDynamics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CardioDynamics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether impedance cardiography (ICG) parameters can predict favorable or&#xD;
      unfavorable blood pressure (BP) response and time to BP control prior to initiation or&#xD;
      intensification of specific antihypertensive drug classes and drug combinations, independent&#xD;
      of initial BP levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients with higher vascular resistance index and/or lower arterial compliance index&#xD;
           will lower BP faster and to a greater degree overall when receiving vasodilating agents&#xD;
           - such as ACEI's, ARB's, dihydropyridine CCB's, direct vasodilators, and central alpha&#xD;
           agonists.&#xD;
&#xD;
        -  Patients with an elevated cardiac index will lower BP faster and to a greater degree&#xD;
           overall when receiving agents that reduce contractility, heart rate, or blood volume -&#xD;
           such as beta blockers, non-dihydropyridine CCB's, and other agents that are known to&#xD;
           reduce cardiac index.&#xD;
&#xD;
        -  Patients with an elevated thoracic fluid content or lower orthostatic change in thoracic&#xD;
           fluid content will lower BP faster and to a greater degree overall when receiving&#xD;
           diuretics (thiazide, loop, potassium sparing), however - one of these agents will emerge&#xD;
           as a superior alternative to reduce BP in patients with high thoracic fluid content /&#xD;
           low orthostatic change in thoracic fluid content.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if ICG can predict therapeutic response to antihypertensive medications</measure>
    <time_frame>2009-2010</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To confirm derivation phase of ICG prediction to therapeutic response of antihypertensive medications.</measure>
    <time_frame>2010-2011</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>ICG</arm_group_label>
    <description>Group will have results blinded during observational phase of study. Results will be revealed at time of testing during the validation phase of the study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited form a population of subjects presenting to a specialty&#xD;
        hypertension clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 18 years of age&#xD;
&#xD;
          -  Able to provide written consent&#xD;
&#xD;
          -  Meet JNC definition of hypertension&#xD;
&#xD;
          -  Lab results with 6 months for: serum creatinine, urine albumin/creatinine ratio, and&#xD;
             at least one of the following: serum glucose, or glycated hemoglobin, or hemoglobin&#xD;
             A1C&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active cardiovascular disease (unstable angina, stage C or D heart failure,&#xD;
             uncontrolled superventricular arrhythmia, hx of ventricular arrhythmia, stroke or TIA&#xD;
             within 6 months, ACS within 6 months)&#xD;
&#xD;
          -  Implantation of activated ventricular pacemaker&#xD;
&#xD;
          -  Known hypersensitivity or allergy to sensor gel or adhesives&#xD;
&#xD;
          -  Skin lesions prohibiting sensor placement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M Flack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University, and Detroit Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Maysura</last_name>
      <phone>313-745-2378</phone>
    </contact>
    <investigator>
      <last_name>John Flack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>June 1, 2009</study_first_submitted>
  <study_first_submitted_qc>June 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2009</study_first_posted>
  <last_update_submitted>June 9, 2009</last_update_submitted>
  <last_update_submitted_qc>June 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2009</last_update_posted>
  <responsible_party>
    <name_title>Rhonda Rhyne, President</name_title>
    <organization>CardioDynamics</organization>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

